Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | DFF332 |
Synonyms | |
Therapy Description |
DFF332 inhibits HIF-2alpha and blocks its DNA binding, which may lead to downregulation of HIF-2alpha target genes involved in tumor cell growth and survival (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
DFF332 | DFF 332|DFF-332 | HIF2A Inhibitor 6 | DFF332 inhibits HIF-2alpha and blocks its DNA binding, which may lead to downregulation of HIF-2alpha target genes involved in tumor cell growth and survival (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04895748 | Phase I | DFF332 + Spartalizumab + Taminadenant DFF332 + Everolimus DFF332 | DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies | Active, not recruiting | USA | ITA | FRA | ESP | CZE | 2 |